Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal STAR-T Cell in Relapsed/Refractory Autoimmune Diseases
NCT07599280Phase 1Not yet recruiting
- Sponsor
- Jian Zhu
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YTS-109 in immune thrombocytopenia (ITP), sponsored by Jian Zhu. Primary endpoint: Dose-Limiting Toxicities at 28 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
YTS-109
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07599280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599280.